Significantly, inhibiting the pro-survival ATM–Akt pathway resulted in (i) enhanced anti-cancer activity (S)-crizotinib; (ii) enhanced anti-tumor activity of (S)-crizotinib in the xenograft GC mice, and (iii) re-sensitized resistant cells to (S)-crizotinib. Here, ATM is linked to gastric cancer.